Esophageal Organoid Medium Composition for High-Passage Success
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protocols for generating esophageal cancer patient-derived organoids (PDOs) have a low success rate, with only about 60% of PDOs able to be successfully passaged ten or more times, limiting their utility for extensive research and therapeutic testing.
Innovation Solution
The development of a novel organoid medium comprising a solubilized membrane matrix, specific concentrations of TGF-β inhibitors, and reduced levels of epidermal growth factor (EGF), along with additional supplements and a feeder layer of cancer-associated fibroblasts, enhances the production and passaging of esophageal organoids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current protocols for generating esophageal cancer PDOs are used, then the process is simple and well-established, but the success rate of producing PDOs that can be successfully passaged ten or more times is only about 60%
Solution Approach 1:
The patent modifies the chemical parameters of the organoid culture medium by adjusting the concentration of EGF from standard levels to reduced levels (less than 50 ng/ml), optimizing TGF-β inhibitor concentrations (about 1 μM to about 20 μM), and specifying precise concentrations of other growth factors and supplements. These parameter changes directly address the low passaging success rate while maintaining manageable protocol complexity.
Solution Approach 2:
The patent creates a composite culture medium formulation that integrates multiple components in specific ratios: solubilized membrane matrix (MATRIGEL), reduced EGF, TGF-β inhibitors, R-spondin, Noggin, and N-acetyl-L-cysteine. This composite approach synergistically improves PDO passaging success beyond what any single component could achieve alone.
2Productivity
If the organoid medium is optimized to increase passaging success rate, then more PDOs can be successfully sub-cultured for at least 10 passages, but the medium composition becomes more complex with specific concentrations of multiple factors
Solution Approach 1:
The patent establishes specific parameter ranges for medium components: EGF less than 50 ng/ml, TGF-β inhibitors at about 1 μM to about 20 μM, R-spondin at 4%, Noggin at 4%, and N-acetyl-L-cysteine at 1.25 mmol/L. These defined parameters enable reproducible high-throughput production of passable PDOs while providing clear preparation protocols that manage formulation complexity.
Solution Approach 2:
The optimized medium formulation includes components that work synergistically to maintain organoid health and proliferation capacity through multiple passages. The combination of growth factors, inhibitors, and supplements creates a self-sustaining culture environment that reduces the need for frequent medium changes and manual interventions, thereby increasing productivity.
Data Source
AI summary
Media for making esophageal organoids, methods of making an esophageal organoid using that media, and esophageal organoids produced by those methods